β受体阻滞剂的心脏保护作用__培训课件.pptVIP

COPERNICUS试验 Months 0 3 6 9 18 15 12 21 50 80 70 60 90 100 Survival (%) Months 0 3 6 9 18 15 12 21 0 60 40 20 80 100 Event-free survival (%) All-cause mortality and hospitalization for any reason 35% relative risk reduction (95% CI 19 – 48%) P=0.00013 P=0.0014 adjusted for interim analysis 24% relative risk reduction (95% CI 13 – 33%) P0.001 Placebo Carvedilol Packer et al. N Engl J Med.2001;344:1651-8 0 250 随访（月） 死亡率 (%) 0 3 6 9 12 15 18 21 20 15 10 5 0 安慰剂 美托洛尔CR/XL MERIT-HF CIBIS II 生存率 300 150 卡维地洛 (n=696) 安慰剂 (n=398) 时间(天) 50 100 200 350 400 1.0 0.9 0.8 0.7 0.6 0.5 USC